Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wm Kevin Kelly

Showing results (1-10 of 37) with videos related to

Pageof 4
Sort By:
Clinical Advances in Hematology & Oncology : H&O|May 28, 2024
STEAP1 as a potential target for new therapies in prostate cancerWm Kevin Kelly
Cancer Journal (Sudbury, Mass.)|February 28, 2008
New drugs in the management of advanced prostate cancerWm Kevin Kelly
Clinical Advances in Hematology & Oncology : H&O|September 16, 2005
Histone deacetylase inhibitorsWm Kevin Kelly
Cancer Journal (Sudbury, Mass.)|April 28, 2007
Histone deacetylase inhibitors: biology and mechanism of actionJanice M Mehnert, Wm Kevin Kelly
The Canadian Journal of Urology|April 30, 2014
Practical guide to the use of enzalutamideJean Hoffman-Censits, Wm Kevin Kelly
Update on Cancer Therapeutics|August 6, 2009
TROG 96.01: TTBF and PSAdt as surrogates for disease specific mortalityChristopher J Hoimes, Wm Kevin Kelly
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 10, 2013
Enzalutamide: a novel antiandrogen for patients with castrate-resistant prostate cancerJean Hoffman-Censits, Wm Kevin Kelly
Seminars in Oncology|June 29, 2013
Targeting epigenetics for the treatment of prostate cancer: recent progress and future directionsJianqing Lin, Chenguang Wang, Wm Kevin Kelly
JAMA Oncology|June 16, 2022
To Treat or Not to Treat Men With Low-risk or Intermediate-risk Prostate Cancer-Weighing the EvidenceSusan Halabi, Bradley C Carthon, Wm Kevin Kelly
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2015
CCR 20th Anniversary Commentary: Vorinostat-Gateway to Epigenetic TherapyWm Kevin Kelly, Paul Marks, Victoria M Richon
Pageof 4

Showing results (1-10 of 37) with videos related to

Sort By:
Pageof 4
Clinical Advances in Hematology & Oncology : H&O|May 28, 2024
STEAP1 as a potential target for new therapies in prostate cancerWm Kevin Kelly
Cancer Journal (Sudbury, Mass.)|February 28, 2008
New drugs in the management of advanced prostate cancerWm Kevin Kelly
Clinical Advances in Hematology & Oncology : H&O|September 16, 2005
Histone deacetylase inhibitorsWm Kevin Kelly
Cancer Journal (Sudbury, Mass.)|April 28, 2007
Histone deacetylase inhibitors: biology and mechanism of actionJanice M Mehnert, Wm Kevin Kelly
The Canadian Journal of Urology|April 30, 2014
Practical guide to the use of enzalutamideJean Hoffman-Censits, Wm Kevin Kelly
Update on Cancer Therapeutics|August 6, 2009
TROG 96.01: TTBF and PSAdt as surrogates for disease specific mortalityChristopher J Hoimes, Wm Kevin Kelly
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 10, 2013
Enzalutamide: a novel antiandrogen for patients with castrate-resistant prostate cancerJean Hoffman-Censits, Wm Kevin Kelly
Seminars in Oncology|June 29, 2013
Targeting epigenetics for the treatment of prostate cancer: recent progress and future directionsJianqing Lin, Chenguang Wang, Wm Kevin Kelly
JAMA Oncology|June 16, 2022
To Treat or Not to Treat Men With Low-risk or Intermediate-risk Prostate Cancer-Weighing the EvidenceSusan Halabi, Bradley C Carthon, Wm Kevin Kelly
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2015
CCR 20th Anniversary Commentary: Vorinostat-Gateway to Epigenetic TherapyWm Kevin Kelly, Paul Marks, Victoria M Richon
Pageof 4